c-Kit (V559A)

KIT · Variant type: point · HGVS: p.V559A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Avapritinib	99.6%	0.4%	97.73
2	Ripretinib	99.4%	0.6%	92.95
3	Tivozanib	98.8%	1.2%	92.42
4	Dasatinib	98.8%	1.2%	87.97
5	Erdafitinib	98.7%	1.3%	95.71
6	Ponatinib	98.5%	1.5%	78.23
7	Apatinib	98.4%	1.6%	97.73
8	Nintedanib	98.2%	1.8%	90.23
9	Sorafenib	97.9%	2.1%	96.72
10	Selpercatinib	97.9%	2.1%	96.72
11	Pacritinib	97.8%	2.2%	88.64
12	Pralsetinib	97.5%	2.5%	93.43
13	Nilotinib	97.4%	2.6%	96.49
14	Brigatinib	96.7%	3.3%	82.96
15	Sunitinib	95.5%	4.5%	91.73
16	Axitinib	95.2%	4.8%	93.23
17	Imatinib	94.7%	5.3%	99.00
18	Quizartinib	94.6%	5.4%	99.50
19	Gilteritinib	94.2%	5.8%	88.97
20	Vandetanib	93.5%	6.5%	95.74
21	Fedratinib	93.5%	6.5%	96.21
22	Umbralisib	92.7%	7.3%	98.74
23	Cabozantinib	91.7%	8.3%	92.73
24	Pexidartinib	91.5%	8.5%	99.49
25	Regorafenib	89.9%	10.1%	95.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Avapritinib	99.6%	—	—
Ripretinib	99.4%	—	—
Tivozanib	98.8%	—	—
Dasatinib	98.8%	—	—
Erdafitinib	98.7%	—	—
Ponatinib	98.5%	—	—
Apatinib	98.4%	—	—
Nintedanib	98.2%	—	—
Sorafenib	97.9%	—	—
Selpercatinib	97.9%	—	—
Pacritinib	97.8%	—	—
Pralsetinib	97.5%	—	—
Nilotinib	97.4%	—	—
Brigatinib	96.7%	—	—
Sunitinib	95.5%	—	—
Axitinib	95.2%	—	—
Imatinib	94.7%	—	—
Quizartinib	94.6%	—	—
Gilteritinib	94.2%	—	—
Vandetanib	93.5%	—	—
Fedratinib	93.5%	—	—
Umbralisib	92.7%	—	—
Cabozantinib	91.7%	—	—
Pexidartinib	91.5%	—	—
Regorafenib	89.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms